Hepatoma Research has made excellent progress and breakthroughs in 2022. At this moment, the Editorial Office would like to express our heartfelt appreciation for continuous support from the Editorial Board members, authors, reviewers and readers. In the past year, the journal has been committed to publishing valuable research results with the joint efforts of many international influential researchers in the field of liver cancer.
The annual report of the journal is as follows:
1. Editorial Board
In 2022, 4 more extraordinary scholars joined Hepatoma Research. As of December 31, 2022, Hepatoma Research has 136 Editorial Board members from over 12 countries, including China, Italy, the USA, South Korea, Germany, Japan, Singapore, Greece, Spain, Australia, the UK, Brazil, etc.
The Authors of Hepatoma Research in 2022 are from over 21 countries and regions, including Italy, the USA, China, Japan, Switzerland, Greece, the UK, Singapore, Spain, Canada, etc. Many of the authors work in the world-renowned institutes, including Yale School of Medicine, USA; University of Washington, USA; Cedars-Sinai Medical Center, USA; Houston Liver Institute, USA; University of Pittsburgh Medical Center, Italy; IRCCS San Raffaele Scientific Institute, Italy and The University of Hong Kong, China, etc.
The Readers of Hepatoma Research are globally distributed, covering more than 197 countries and regions, including the USA (31.27%), India (8.80%), China (7.69%), the UK (4.19%), Egypt (3.15%), South Korea (2.80%), Italy (2.77%), Canada (2.38%), Australia (2.22%), Taiwan (China) (1.99%), etc.In 2022, the number of readers from the USA raised remarkably. Meanwhile, Australia and Canada are going to continue to be the increasing percentage of the total readership distribution.
4. Highly Cited Papers
Hepatoma Research totally received 99 papers in 2022, with 41 papers published online, including 21 reviews, 8 original articles, 6 editorial, 3 perspectives, 2 erratum articles and 1 case report with 50, 772 total article views and 14, 846 total article downloads in 2022. The journal adheres to publishing valuable scientific research, 58 papers were rejected after rigorous and standard peer-review, accounting for nearly 60% of all the submissions.
Besides, 13 published papers got financial support and sponsorship. Here are some highly cited papers for recommendation in 2022:
(1) Minimally invasive surgery for HCC
(2) The role of minimally invasive surgery in the treatment of HCC
(3) Robotic donor hepatectomy: a niche advancement or the way forward? A perspective from the world's largest center
(4) Histopathology of Hepatocellular Carcinoma-When and What
(5) Role of locoregional therapies in the management of patients with hepatocellular carcinoma
(6) Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
(7) Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma
As of December 31, 2022, Hepatoma Research held 5 webinars focusing on different hot topics. A total of over 400 audiences registered and participated in the academic sharing activities. These international researchers shared and discussed their knowledge and studied together and strengthened the academic circle of researchers in the field of liver cancer.
(1) Current Therapeutic Strategies in Nonalcoholic Fatty Liver Disease
Chair: Matthew M. Yeh, Professor of Laboratory Medicine and Pathology, Adjunct Professor of Medicine; Director, Gastrointestinal and Hepatic Pathology Program, University of Washington, Seattle, WA, USA.
(2) Diet, Liver Diseases, Liver Cancer: Prevention from the Source
Chair: Ludovico Abenavoli, Associate Professor, Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
(3) Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma
Chair: Timothy M. Pawlik, Professor and Chair, Department of Surgery; The Urban Meyer III and Shelley Meyer Chair for Cancer Research; Professor of Surgery, Oncology, and Health Services Management and Policy; Surgeon in Chief, the Ohio State University Wexner Medical Center, Columbus, OH, USA.
(4) Liver Tumors of Unidentified Primary: are All HCC or HCC-CCA?
Chair: Tania Roskams, Professor, Head of Department of Imaging and Pathology, Translational Cell and Tissue Research, Katholieke Universiteit Leuven and University Hospitals Leuven, Leuven, Belgium.
(5) Liver Transplantation for Hepatocellular Carcinoma: Up to Date
Chair: Pierluigi Toniutto, Assistant Professor of Medicine, Director of Hepatology and Liver Transplant Unit, University of Udine, Udine, Italy.
Many attendees spoke highly of the arrangements by the Editorial Office for the scholars, including Ming-Lung Yu, Senior Vice President, Dean and Chair Professor, School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan; Stephen A. Harrison, Chairman- Summit Clinical Research, Chairman- Pinnacle Clinical Research, San Antonio, TX, USA; Swan N. Thung, Professor of Pathology, Molecular and Cell-Based Medicine; Director of Hepatopathology Division, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Vincenzo Mazzaferro, Full Professor of Surgery at the Department of Oncology of the University of Milan and Director of the Gastro-Intestinal Surgery and Liver Transplantation Unit at the Istituto Nazionale Tumori (National Cancer Institute), Milan, Italy; Jessica Zucman-Rossi, President of the International Liver Cancer Association (ILCA), Professor of Oncology in University Paris Descartes and director of the Inserm Unit "Functional Genomic of Solid Tumors", Paris, France; Patrizia Burra, Professor of Gastroenterology and Head of the Multivisceral Transplant Unit, University Hospital Padua, Italy; Umberto Cillo, Professor of General Surgery from the University of Padova, Director at the University of Padova, Padua, Italy; and Jan Lerut, Professor Emeritus of Surgery, Director of the Starzl Abdominal Transplant Unit, University Hospitals Saint Luc and UCL Transplant Centre in Brussels, and Past President of European Society of Organ Transplantation and International Society of Liver Transplantation, Brussels, Belgium. The journal has made further cooperation with the Chairs and these participants after the webinars. 3 Special Issues based on the webinar topics have been established, edited by the Chairs Prof. Timothy M. Pawlik, Prof. Tania Roskams and Prof. Pierluigi Toniutto respectively.
6. Journal Partners
Hepatoma Research is committed to disseminating scientific research and promoting scientific innovation in the liver cancer field and will adhere to publishing more valuable and high-quality papers as well as bringing more wonderful symposiums in the future.